RxDoctor Payments Data

Frederick Marshall, MD

Neurology · Rochester, NYNPI 1710906391

Payments from drug & device makers

$387,270in general payments, 2019–2025

Across 194 payments — averaging $1996.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$386K
  • Teva Pharmaceuticals USA, Inc.$896

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$387,270 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$26,222
Medicare patients
155
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine23$231,197
RytaryCarbidopa/Levodopa11$21,410
Memantine Hcl518$13,725
Rivastigmine37$7,877
Carbidopa-LevodopaCarbidopa/Levodopa135$7,136
Memantine Hcl ErMemantine Hcl41$4,940
Donepezil Hcl230$2,115
Carbidopa-Levodopa ErCarbidopa/Levodopa40$1,174
RivastigmineRivastigmine Tartrate17$814
Escitalopram Oxalate91$740
Levetiracetam19$451
Mirtazapine17$424
Lamotrigine11$364
Risperidone37$276
Quetiapine Fumarate25$163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$896$231,19723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.

Other neurology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →